Communiqués 2cureX AB

Actions

2CUREX

SE0010468124

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Stockholm 18:00:00 19/08/2026			Varia. 5j.	Varia. 1 janv.
0,4600 ^SEK	-13,37%		-71,53%	-10,51%

18/08	2cureX annonce son retrait de la cote du Nasdaq First North Growth Market	MT
18/08	Nasdaq retire 2curex de la cote du First North : fin des négociations le 31 août	FW

Communiqués

18/08	Nasdaq decides to delist 2cureX AB	AQ
06/07	2cureX AB accelerates reintegration of operating business into the listed company	AQ
25/06	2cureX : The Directed Issue announced 22 April 2026 will be registered at Bolagsverket under the authorization granted by the Annual General Meeting held on 25 June 2026.	PU
25/06	Communiqué from the Annual General Meeting on Thursday 25 June 2026 in 2cureX AB	AQ
28/05	THIS PRESS RELEASE IS AN ENGLISH TRANSLATION OF THE LEGALLY BINDING SWEDISH PRESS RELEASE: “PUBLICERING AV ÅRSREDOVISNINGEN FÖR 2CUREX AB (publ)”.	AQ
25/05	Notice of annual general meeting in 2cureX AB	AQ
20/05	2cureX AB Expands Functional Precision Medicine Infrastructure Through Strategic Collaboration with StoreMyTumor	AQ
19/05	2cureX AB’s Executive Management is pleased to invite shareholders and investors to a live webcast and business update on 20 May at 7pm CET.	AQ
22/04	2cureX AB completes oversubscribed directed issue	AQ
26/02	2cureX AB (publ) publishes Interim Report for the Second Half of 2025	AQ
29/08/25	CEO Nathaniel Hutley presents a strategic update on 2cureX’s new Website Blog.	AQ
21/08/25	2cureX AB (“2cureX”) hereby publishes the interim report for the first half year of 2025.	AQ
11/07/25	Improved communication from 2cureX AB	AQ
02/07/25	Correction: CEO Nathaniel Hutley presents latest news from 2cureX on July 2nd 2025.	AQ
01/07/25	2cureX AB is in the process of securing a strategic collaboration with PreComb Therapeutics AG.	AQ
13/06/25	CEO Nathaniel Hutley presents latest news from 2cureX on July 2nd 2025.	AQ
30/05/25	NOTICE OF ANNUAL GENERAL MEETING OF 2CUREX AB (publ).	AQ
29/05/25	RELEASE OF THE 2CUREX AB (PUBL) ANNUAL REPORT	AQ
22/05/25	2cureX appoints Mangold Fondkommission AB as new Certified Adviser	AQ
20/05/25	2cureX Conducts First Direct-to-Patient IndiTreat® Test Under “Operation Twin Code” Strategy	AQ
15/05/25	2cureX AB (2CUREX) Launches “Operation Twin Code” with New Investors, Leadership Transition, and Global Roadmap	AQ
14/04/25	EARLY NOTICE OF ANNUAL GENERAL MEETING OF 2CUREX AB (publ)	AQ
27/02/25	2cureX publishes interim report for the second half year of 2024	AQ
18/12/24	BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING IN 2CUREX AB (PUBL)	AQ
16/12/24	2cureX AB Announces the Appointment of Dan Honeywell as CEO, Ushering in a New Era of commercial expansion of breakthrough precision oncology products	AQ